Caris Life Sciences (CAI) Director Peter Castleman Receives RSU Award

What Happened
Peter M. Castleman, a director of Caris Life Sciences, received an award of 13,192 restricted stock units (RSUs) on 2026-08-14. The Form 4 reports an acquisition at $0.00 (total reported value $0) because this is an equity award, not an open‑market purchase. RSUs typically convert to shares if and when they vest according to the grant terms, so this is a compensation/award transaction rather than a purchase or sale.

Key Details

• Transaction date: 2026-08-14; Transaction code: A (award/grant).
• Shares/units granted: 13,192 RSUs; reported price: $0.00; reported total value: $0.
• Shares owned after transaction: not specified in the provided filing excerpt (see the full Form 4 for total holdings).
• Footnotes: F1 — RSUs vest in accordance with the applicable grant agreement; F2 — includes shares received in pro rata distributions exempt under Rule 16a-9; F3 — Mr. Castleman has voting and investment power for shares held by CLS-PF-SPE, LLC through CLS-PF-SPE Manager, LLC and disclaims beneficial ownership except for his pecuniary interest.
• Filing timeliness: Reported date equals period of report (filed 2026-08-14) — not indicated as late.

Context
RSU grants are commonly used as compensation and only convert into tradable shares if/when vesting conditions are met; they do not represent an immediate purchase or sale. Because this is an award, it’s primarily informative about executive/director compensation and potential future share issuance rather than a direct buy/sell signal. For full ownership context and vesting schedule, consult the complete Form 4 and the underlying grant agreement.